InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,463.54
(
0.00%
)
US TECH 100
18,615.20
(
0.32%
)
Dow Jones
40,539.93
(
0.00%
)
Brent Oil
78.34
(
-1.02%
)
Bitcoin
66,647.66
(
-0.26%
)
Post# of 29487
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120153
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Bickema post# 14472

Thursday, 11/09/2017 10:54:09 AM

Thursday, November 09, 2017 10:54:09 AM

Post# of 29487
AZN sales in China are booming—despite lackluster RoW results:

https://uk.reuters.com/article/uk-astrazeneca-results-china/astrazeneca-rides-china-wave-as-rival-glaxosmithkline-struggles-idUKKBN1D91RR

China revenue in the third quarter increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales - a far higher proportion than at other big pharma companies.

… straZeneca has had five new products recently added to the country’s National Reimbursement Drug List - Onglyza for diabetes, cancer drugs Iressa and Faslodex, heart medicine Brilinta and antipsychotic treatment Seroquel.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up